Cargando…

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

The objective was to leverage tumor size data from preclinical experiments to propose a model of tumor growth and angiogenesis inhibition for the analysis of pazopanib efficacy in renal cell carcinoma (RCC) patients. We analyzed tumor data in mice with RCC CAKI‐2 cell line treated with pazopanib. Cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouerdani, A, Struemper, H, Suttle, AB, Ouellet, D, Ribba, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716582/ https://www.ncbi.nlm.nih.gov/pubmed/26783502 http://dx.doi.org/10.1002/psp4.12001

Ejemplares similares

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014)

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
por: Pick, Amy M., et al.
Publicado: (2013)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()
por: Li, Haifu, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma
por: Klein, Jonah D., et al.
Publicado: (2014)

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
por: Méndez-Vidal, María José, et al.
Publicado: (2018)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
por: BALL, DOUGLAS W., et al.
Publicado: (2015)

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
por: Harrison, Michael R.
Publicado: (2011)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

One year survivor of metastatic renal cell carcinoma treated with pazopanib
por: Inn, Fam Xeng, et al.
Publicado: (2017)

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
por: Wood, Christopher G., et al.
Publicado: (2020)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
por: Roberto, Michela, et al.
Publicado: (2015)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient
por: Porta, Camillo, et al.
Publicado: (2017)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
por: Wu, Xiao Yu, et al.
Publicado: (2015)

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
por: Jeon, So-Yeon, et al.
Publicado: (2019)

ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma
por: Carew, Jennifer S., et al.
Publicado: (2012)

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights
por: Chiabotto, Giulia, et al.
Publicado: (2020)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
por: Narukawa, Tsukasa, et al.
Publicado: (2020)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
por: Villa, Guillermo, et al.
Publicado: (2013)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

A Case of Cardiac Tamponade in a Patient with Metastatic Renal Cell Carcinoma on Pazopanib Treatment
por: Sarathy, Vinu, et al.
Publicado: (2020)

Durable Response to Pazopanib in a Patient with Fumarate Hydratase-Mutant Tubulocystic Renal Cell Carcinoma
por: Othman, Anjum, et al.
Publicado: (2023)

Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma
por: Zhu, Li Ming, et al.
Publicado: (2014)

Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor
por: Shi, W, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_46dlopkdso3l69fmis5gae2hot